Thank you, Todd, and good morning, everyone. Let me start by saying that I'm excited about my new role as interim CFO and look forward to working with the investor and analyst community. We are pleased with the value created through JV contributions and asset sale this year. Through October, proceeds totaled $875 million. Based on this success, we are increasing our full year proceeds range to $1.05 billion to $1.15 billion, up $100 million at the midpoint. Since our last call, we've repurchased over $150 million of additional shares, bringing year-to-date repurchases to nearly $450 million at a weighted average share price of $16.48. On a leverage-neutral basis, this represents a reinvestment spread to the company of over 100 basis points, a highly accretive outcome for earnings, cash flow and NAV. As we look ahead, there is currently a deep and liquid market for medical outpatient buildings and HR has ample access to that market via third-party asset sales and its joint venture partnerships. We will target the highest long-term risk-adjusted returns for shareholders through a dynamic capital allocation framework which will always take into account the valuation and future growth embedded in our own portfolio. Turning to the balance sheet. In October, we used proceeds from asset sales to fully repay the unsecured term loan set to mature in July of 2025. Including this debt repayment, quarter end net debt to adjusted EBITDA would have been 6.6x. We expect leverage to decline to 6.5x at the end of 2024 and continued to move lower in 2025 driven by our organic growth. Finally, as of the end of the quarter, we had approximately $1.3 billion of availability under our credit facility, providing substantial financial flexibility. With almost 350,000 square feet of multi-tenant absorption year-to-date, we are investing significant capital in new leasing at very high risk-adjusted returns. As Todd mentioned, this new leasing activity is only beginning to produce a corresponding NOI benefit. Due to the timing mismatch between capital spend and cash rent from new leasing, our payout ratio was 106% in the quarter. Excluding the impact of absorption capital, our payout ratio would have been 98%. Over the course of 2025, we expect our payout ratio to decline below 100% and approach 90% adjusted for absorption capital. Now I'd like to provide an update on the Steward bankruptcy process, which is unfolding in real time. In recent days, we have gained additional clarity. As a reminder, our total exposure to Steward leases is approximately $27 million of annual NOI across 593,000 square feet. We have secured or have high visibility into leases with new tenants for approximately $17 million of annual NOI or nearly two thirds of our total exposure. This includes $12 million in new direct leases with Boston Medical Center and Brown University Health. These solid investment-grade nonprofit systems represent fantastic upgrades in credit quality as well as new health system partnerships. The remaining $10 million of annual NOI represents leases that were not accepted by new operators or where we do not have visibility on near-term replacement leases. The loss of this NOI will begin November 1, and we are assuming that this will continue through 2025. Backfilling space will take time as we work with new tenants and operators to program and build out space. While it's still very early, we are encouraged by the long-term opportunity to recover approximately half of this NOI through our leasing efforts. In summary, we have clarity on almost two thirds of the annual Steward NOI with a longer-term opportunity to recover over 80% of the $27 million of current NOI with greatly improved credit quality and tenant diversification. Turning to guidance. We have narrowed our 2024 normalized FFO per share range to $1.55 to $1.56, including the November and December impact from Steward that I just covered. Our core business is performing extremely well. This performance is generating a number of tailwinds into 2025, including the benefits of absorption accretive capital allocation. I look forward to meeting with many of you over the next two months at conferences. With that, I will now turn it back to the operator to open the line for questions. Operator?